Celecoxib exhibits therapeutic potential in experimental model of hyperlipidaemia.
Hyperlipidaemia is a major risk factor for cardiovascular diseases, the leading cause of death globally. Celecoxib attenuated hypercholesterolaemia associated with CCl4-induced hepatic injury in rats without improving liver function in our previous study. This present study investigated the lipid lo...
Guardado en:
Autores principales: | Martins Ekor, Phyllis Elsie Owusu Agyei, Ernest Obese, Robert Peter Biney, Isaac Tabiri Henneh, Meshack Antwi-Adjei, Ewura Seidu Yahaya, Gordon Amoakohene, Patrick Kafui Akakpo |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Public Library of Science (PLoS)
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/b28e6cd8d910428ab561d668c2da7962 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Glucose inhibits haemostasis and accelerates diet-induced hyperlipidaemia in zebrafish larvae
por: Simone Morris, et al.
Publicado: (2021) -
Global and hepatocyte-specific ablation of Bmal1 induces hyperlipidaemia and enhances atherosclerosis
por: Xiaoyue Pan, et al.
Publicado: (2016) -
Virtual patient simulation platforms challenging traditional CME: Identification of gaps in knowledge in the management of Type 2 diabetes and Hyperlipidaemia
por: Igal Iancu, et al.
Publicado: (2021) -
Effects of Celecoxib Adjunct to Selective Serotonin Reuptake Inhibitors on Obsessive-Compulsive Disorder
por: Najmeh Shahini, et al.
Publicado: (2021) -
Cost-effectiveness analysis of branded and authorized generic celecoxib for patients with chronic pain in Japan.
por: Yusuke Karasawa, et al.
Publicado: (2021)